. Author manuscript; available in PMC: 2019 Jun 13.

Published in final edited form as: Int J Tuberc Lung Dis. 2017 Jan 13;21(3):286–296. doi: 10.5588/ijtld.16.0469

Table A.8.

Completion of follow-up status by completion of treatment among first participants enrolled in a cluster in the North American region (n = 5228)^*

	Did not complete treatment (n = 1247)		Completed treatment (n = 3981)
	Did not complete follow-up (n = 330)	Completed follow-up (n = 917)	Did not complete follow-up (n = 320)	Completed follow-up (n = 3661)
Regimen^†	n (%)	n (%)	n (%)	n (%)
3HP-DOT (n = 2590)	117 (35.5)	366 (39.9)	178 (55.6)	1929 (52.7)
9H-SAT (n = 2638)	213 (64.6)	551 (60.1)	142 (44.4)	1732 (47.3)
Total (n = 5228)	330 (26.5)^‡	917 (73.5)^‡	320 (8.0)^§	3661 (92.0)^§

Participants had the opportunity to continue study follow-up after completion or discontinuation of treatment. The proportion of non-completion of follow-up between those who did not complete treatment (26.5%) vs. those who completed treatment (8.0%) was statistically significant (P < 0.001).

^†

3HP-DOT = 3 months of directly observed once-weekly RPT (maximum dose, 900 mg) plus INH (maximum dose, 900 mg); 9H-SAT = 9 months of daily self-administered INH (maximum dose, 300 mg).

^‡

The denominator is all participants who did not complete treatment (n = 1247).

^§

The denominator is all participants who completed treatment (n = 3981).

H, INH = isoniazid; P, RPT = rifapentine; DOT = directly observed therapy; SAT = self-administered treatment.